Skip to main content
Caplight Logo









Kither Biotech

Kither Biotech

Private
TurinHealthcare & Life Scienceshttps://kitherbiotech.com/

Last Round

Series B

Mar 16, 2022

Total Funding Raised

$26.58M

Company Overview

Kither Biotech is a biotechnology company developing signal transduction modulators for the treatment of rare respiratory diseases such as cystic fibrosis and idiopathic pulmonary fibrosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalcystic fibrosisdrug discoveryrare respiratory diseasessmall-molecule drugsclinical trialsbiotechpeptide drug discoverydrug licensingCFTR proteinclinical-stage biotechpharma partnershiporphan drugsdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kither Biotech Comparables

Compare Kither Biotech with similar companies based on industry and business-model similarity.

Kither Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enterprise Therapeutics
86%
ReCode Therapeutics
79%
Aer Therapeutics
77%

Kither Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 16, 2022
Series AJul 5, 2019

Key People

Founding team and executive leadership

Dimitrios Goundis

Chief Executive Officer

Executive Team

Kither Biotech Investors

Notable investors and investment history

Kither Biotech investors
InvestorRounds
Elysia CapitalSeries A
3B FUTURE Health FundSeries B
Moschini SpaSeries A
Club degli InvestitoriSeries A, Series B
Claris VenturesSeries B
2invest AGSeries B
CDP Venture Capital SGRSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 35% MoM, reaching 1K.

  • Mar 16, 2022

    $20.26M raised in Series B funding.

Kither Biotech Filings

Explore SEC and related filing metadata, where available.

Kither Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kither Biotech's valuation, stock price, and market status.

Is Kither Biotech a public or private company?

Kither Biotech is a private company.

What is the current stock price of Kither Biotech?

Kither Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Kither Biotech worth (valuation)?

Valuation information for Kither Biotech is not publicly available.

Can I buy Kither Biotech stock?

Kither Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Kither Biotech's last funding round?

Kither Biotech's most recent funding round was Series B on March 16, 2022.

Who are the main investors in Kither Biotech?

Key investors in Kither Biotech include Claris Ventures, 2invest AG.

Will Kither Biotech IPO soon?

No public IPO plans have been announced for Kither Biotech.

How can I track Kither Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kither Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTurin
Employee Range15
Year Founded2011
Last FundingMar 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?